secwatch.observer — SEC 8-K summary
======================================

Issuer:     PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
CIK:        0001299130
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0001104659-24-047511
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PacBio reports preliminary Q1 rev $38.8M (flat YoY), slashes FY2024 guidance to $170-200M, cuts costs $50-75M
--------------------------------------------------------------------------------

- Preliminary Q1 2024 revenue $38.8M, roughly flat vs $38.9M in prior-year period.
- Revio shipments 28 systems in Q1; installed base reached 201 as of March 31, 2024.
- FY2024 revenue guidance reduced to $170-200M; long-term $500M 2026 goal unlikely.
- Plan to reduce annualized non-GAAP operating expense run rate by $50M-$75M by end of 2024.
- Cash, cash equivalents & investments expected to be $435-450M by year-end, down from $562M at Q1 end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1299130/000110465924047511/0001104659-24-047511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1299130/000110465924047511/tm2411926d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-047511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer